Intrust Bank NA lowered its position in Allergan PLC. (NYSE:AGN) by 9.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,810 shares of the company’s stock after selling 199 shares during the quarter. Intrust Bank NA’s holdings in Allergan PLC. were worth $440,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the business. GWM Advisors LLC lifted its position in shares of Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after acquiring an additional 5 shares during the period. Burns J W & Co. Inc. NY lifted its position in shares of Allergan PLC. by 0.7% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after buying an additional 6 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its position in shares of Allergan PLC. by 0.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after buying an additional 9 shares during the period. Trust Co lifted its position in shares of Allergan PLC. by 0.8% during the 1st quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after buying an additional 10 shares during the period. Finally, Berkeley Capital Partners LLC lifted its position in shares of Allergan PLC. by 0.3% during the 2nd quarter. Berkeley Capital Partners LLC now owns 3,721 shares of the company’s stock worth $905,000 after buying an additional 10 shares during the period. Institutional investors own 82.06% of the company’s stock.
AGN has been the subject of several analyst reports. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Mizuho cut their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Royal Bank Of Canada restated a “buy” rating and set a $285.00 target price on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, Cantor Fitzgerald initiated coverage on Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and an average target price of $274.69.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/09/16/intrust-bank-na-trims-holdings-in-allergan-plc-agn.html.
Shares of Allergan PLC. (AGN) opened at 220.29 on Friday. The firm has a market capitalization of $73.64 billion, a PE ratio of 6.71 and a beta of 1.18. The stock has a 50 day moving average price of $231.75 and a 200 day moving average price of $236.59. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the prior year, the company earned $3.35 EPS. Allergan PLC.’s revenue was up 8.8% compared to the same quarter last year. Equities research analysts anticipate that Allergan PLC. will post $16.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.